Home » Stocks » ELOX

Eloxx Pharmaceuticals, Inc. (ELOX)

Stock Price: $4.13 USD -0.05 (-1.20%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 166.63M
Revenue (ttm) n/a
Net Income (ttm) -40.08M
Shares Out 40.14M
EPS (ttm) -1.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $4.13
Previous Close $4.18
Change ($) -0.05
Change (%) -1.20%
Day's Open 4.12
Day's Range 3.90 - 4.23
Day's Volume 101,591
52-Week Range 1.56 - 4.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

The CF Foundation's partial funding of the U.S. trial has been extended to partial funding of the global clinical trial program which includes Europe and Israel

Zacks Investment Research - 4 weeks ago

Eloxx Pharmaceuticals (ELOX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel the...

Seeking Alpha - 2 months ago

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 202 1

GlobeNewsWire - 2 months ago

A Publication titled: “ELX-02: an investigational read-through agent for the treatment of non sen se mutation-related genetic disease” has been published in the Expert Opinion on Investigation...

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel the...

GlobeNewsWire - 3 months ago

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to p...

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel ...

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel t...

GlobeNewsWire - 5 months ago

WALTHAM, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel t...

Seeking Alpha - 5 months ago

Eloxx Pharmaceuticals (ELOX) CEO Greg Williams on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel after being temporarily paused due to the COVID-19 pandemic

GlobeNewsWire - 5 months ago

ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency ELX-02 had previously been granted orphan medicina...

GlobeNewsWire - 5 months ago

WALTHAM, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel t...

GlobeNewsWire - 5 months ago

Company management to host a webcast and conference call to provide a business update and review financial results at 2:00 p.m. ET Company management to host a webcast and conference call to p...

GlobeNewsWire - 6 months ago

ELX-02 mediates read-through of premature stop codons while maintaining the fidelity of native stop codons ELX-02 mediates read-through of premature stop codons while maintaining the fidelity ...

Benzinga - 6 months ago

Eloxx Pharmaceuticals (NASDAQ: ELOX) shares are trading higher on Thursday. The company announced that enrollment in its Phase 2 trial for ELX-02 has resumed in Israel and Europe.

GlobeNewsWire - 6 months ago

WALTHAM, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel t...

Forbes - 7 months ago

It was an overall good week for the market, but the flip to a bearish put-call ratio this morning tells us that there are plenty of volatile stocks poised for short-selling.

Seeking Alpha - 8 months ago

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

These five stocks are poised to grow with the guidelines laid out to reopen the economy, as coronavirus pandemic dissipates.

Other stocks mentioned: AWR, BGCP, RMED, SHSP
GlobeNewsWire - 9 months ago

Enrollment in our Phase 2 Cystic Fibrosis Trials has been paused temporarily in response to the COVID-19 pandemic

Seeking Alpha - 10 months ago

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

Reiterate topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 expected in H1 2020 Results from clinical and preclinical research to date support Company’s prioritization o...

GlobeNewsWire - 1 year ago

Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Eloxx.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Eloxx Pharmaceuticals, Inc. (ELOX).

Seeking Alpha - 1 year ago

Eloxx Preliminary CF Data Should Be Monitored Closely As It Advances Forward

Seeking Alpha - 1 year ago

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Robert Ward on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Results of our renal impairment study for ELX-02 support the expansion of our research in the kidney beyond nephropathic cystinosis into other areas such as autosomal dominant polycystic kidne...

GlobeNewsWire - 1 year ago

CF Foundation and Eloxx to form joint program advisory group focused on the development of ELX-02 for cystic fibrosis

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel ...

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel ...

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel t...

Seeking Alpha - 1 year ago

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Robert Ward on Q2 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

As the market played a waiting game, good news lifted several companies higher.

Other stocks mentioned: AMD, CIEN
Benzinga - 1 year ago

Eloxx Pharmaceuticals (NASDAQ: ELOX) shares spiked higher after the company presented data for its lead investigational drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference.

Seeking Alpha - 1 year ago

Eloxx Pharmaceuticals' (ELOX) CEO Robert Ward on Q1 2019 Results - Earnings Call Transcript

About ELOX

Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Founded
2013
CEO
Robert Ward
Employees
29
Stock Exchange
NASDAQ
Ticker Symbol
ELOX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ELOX stock is "Buy." The 12-month stock price forecast is 5.00, which is an increase of 21.07% from the latest price.

Price Target
$5.00
(21.07% upside)
Analyst Consensus: Buy